Balanced Partnering Approach
We are leaders in the development of novel genomic therapies and have developed unique platform capabilities in gene therapy, genome editing, cell therapy and gene regulation.
With technology that has the potential to edit or regulate virtually any gene in the genome, we believe maximizing shareholder value must include a balanced approach between proprietary and externalized research. Our strategy is to develop our proprietary pipeline of product candidates in our therapeutic areas of focus, including inherited metabolic diseases, CNS diseases and immunology. We collaborate to harness the capabilities and competitive advantages of industry partners for product candidates that require expertise or resources outside our areas of focus.
Interested in Partnering with Us?
Click here to contact Melita Sun Jung, Vice President, Head of Business Development.
Our business strategy is to do what we do best — develop gene therapy, genome editing, cell therapy and gene regulation products through research, preclinical and early stage clinical testing. We then partner when doing so will help us fully realize the value of certain programs through late stage development and commercialization.
Shire International GmbH
Shire plc and Sangamo are developing therapeutics for Huntington's disease utilizing our ZFP-TF gene regulation platform.
ZFPs have applications beyond human therapeutics, from agriculture to generating cell lines for drug testing or manufacturing.
Dow AgroSciences LLC
Dow AgoSciences, a wholly-owned subsidiary of Dow Chemical Corporation, has licensed the exclusive right to use ZFP technology to modify the genomes or alter the nucleic acid or protein expression of plant cells, plants, or plant cell cultures. Dow AgroSciences markets ZFN-mediated genome edited plant products under the trademark EXZACT™ Precision Technology. We have retained rights to use plants or plant-derived products to deliver ZFP TFs or ZFN products into human or animals for diagnostic, therapeutic, or prophylactic purposes.